CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at Cantor Fitzgerald from $6.00 to $10.00. They now have an "overweight" rating on the stock.
CytomX Therapeutics to Present at Upcoming February Conferences [Yahoo! Finance]
CytomX Therapeutics to Present at Upcoming February Conferences
CytomX Therapeutics (NASDAQ:CTMX) was given a new $10.00 price target on by analysts at Barclays PLC.
CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? [Yahoo! Finance]